Cannabinoid WIN55,212-2 reprograms monocytes and macrophages to inhibit LPS-induced inflammation
IntroductionChronic or uncontrolled activation of myeloid cells including monocytes, macrophages and dendritic cells (DCs) is a hallmark of immune-mediated inflammatory disorders. There is an urgent need for the development of novel drugs with the capacity to impair innate immune cell overactivation...
Main Authors: | Mario Pérez-Diego, Alba Angelina, Leticia Martín-Cruz, Andrés de la Rocha-Muñoz, Angel Maldonado, Carmen Sevilla-Ortega, Oscar Palomares |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-03-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2023.1147520/full |
Similar Items
-
Minimum Alveolar Concentration of Isoflurane in Rats Chronically Treated with the Synthetic Cannabinoid WIN 55,212-2
by: Julio Raul Chavez-Monteagudo, et al.
Published: (2022-03-01) -
EFFECTS OF SYNTETIC CANNABINOID RECEPTOR LIGANDS WIN 55.212-2 AND ANANDAMID UPON IN VITRO ACTIVITY OF IMMUNOCOMPETENT CELLS
by: E. G. Lobanova
Published: (2014-07-01) -
A male mouse model of WIN 55,212–2 self-administration to study cannabinoid addiction
by: María del Mar Cajiao-Manrique, et al.
Published: (2023-03-01) -
WIN 55,212-2 Inhibits the Epithelial Mesenchymal Transition of Gastric Cancer Cells via COX-2 Signals
by: Xiangshu Xian, et al.
Published: (2016-11-01) -
Synthetic cannabinoid WIN 55,212–2 inhibits growth and induces cell death of oral and pancreatic stem-like/poorly differentiated tumor cells
by: Meng-Wei Ko, et al.
Published: (2022-10-01)